FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213022402> ?p ?o ?g. }

• W4213022402 endingPage "26" @default.
• W4213022402 startingPage "26" @default.
• W4213022402 abstract "26 Background: The underrepresentation of minority populations in clinical trials negatively impacts cancer and widens inequities. We aimed to quantify the enrollment disparities in prostate cancer (PC) clinical trials over the last three decades. Methods: MEDLINE and Embase were searched to identify primary reports of prostate cancer RCTs (1989-2020). Data for trial characteristics, the proportion of trials reporting race, ethnicity and age, and the proportion of patients by race, ethnicity and age enrolled in trials were summarized using descriptive statistics. Enrollment incidence ratios (EIR), which compare trial enrollment against global estimates of incidence in age-related subgroups (acquired from the Global Burden of Disease database) and U.S. population-based estimates of racial/ethnic subgroups (acquired from the SEER 18 incidence database) were calculated. Individual trial EIRs were pooled using random-effects meta-analyses to account for the substantial heterogeneity between trials. Multivariable meta-regression was used to explore associations between key trial characteristics and EIR. Annual percentage changes (APC) over the last three decades in enrollment disparities were analyzed using the Joinpoint Regression Analysis. Results: 281 trials from 1989 to 2020 with 99,588 patients were included in this analysis. 107 trials reported race (38%), of which only 25 trials (9%) reported data on all 5 U.S. racial categories (Black, White, Asian, Pacific Islander and Native American. 255 (91%) trials reported mean or median but only 71 trials (25%) specifically reported the enrollment proportion of older adults (age > 65 years). Clinical outcomes by race and age were reported in 9 (8%) and 37 (14%) trials, respectively. Results from meta-analyses showed that Black patients (summary EIR: 0.42 [95% CI: 0.35 - 0.51]), Hispanics (summary EIR: 0.50 [95% CI: 0.37 - 0.68]) and older adults (summary EIR: 0.95 [95% CI: 0.91 - 0.99]) were underrepresented in trials relative to their population estimates. Significantly fewer Black participants (EIR for Black patients = 0.42, EIR for White patients = 0.99; p < 0.0001), Hispanic participants (EIR for Hispanics = 0.50, EIR for non-Hispanics = 1.00; p = 0.001) and older adults (EIR for older adults = 0.95, EIR for younger adults = 1.06; p = 0.037) were enrolled. Representation of Black patients decreased significantly from 1989-2019 (APC: -4.25), while Hispanic representation increased significantly from 2000-2020 (APC: 5.89). Meta-regression showed Black patients were particularly underrepresented in larger-size trials (p < 0.0001). Conclusions: Black representation in PC clinical trials is less than 50% of their expected share based on cancer incidence and it has consistently decreased over last three decades, contributing to the disparities experienced by the population." @default.
• W4213022402 created "2022-02-24" @default.
• W4213022402 creator A5017018696 @default.
• W4213022402 creator A5018306647 @default.
• W4213022402 creator A5022249991 @default.
• W4213022402 creator A5028736111 @default.
• W4213022402 creator A5030233600 @default.
• W4213022402 creator A5031306593 @default.
• W4213022402 creator A5036662227 @default.
• W4213022402 creator A5036761306 @default.
• W4213022402 creator A5044194506 @default.
• W4213022402 creator A5052826456 @default.
• W4213022402 creator A5061753488 @default.
• W4213022402 creator A5065226003 @default.
• W4213022402 creator A5067550666 @default.
• W4213022402 creator A5074582149 @default.
• W4213022402 date "2022-02-20" @default.
• W4213022402 modified "2023-09-24" @default.
• W4213022402 title "A quantitative synthesis of disparities in the inclusion of racial/ethnic minorities and older adults in prostate cancer clinical trials over the last three decades." @default.
• W4213022402 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.026" @default.
• W4213022402 hasPublicationYear "2022" @default.
• W4213022402 type Work @default.
• W4213022402 citedByCount "0" @default.
• W4213022402 crossrefType "journal-article" @default.
• W4213022402 hasAuthorship W4213022402A5017018696 @default.
• W4213022402 hasAuthorship W4213022402A5018306647 @default.
• W4213022402 hasAuthorship W4213022402A5022249991 @default.
• W4213022402 hasAuthorship W4213022402A5028736111 @default.
• W4213022402 hasAuthorship W4213022402A5030233600 @default.
• W4213022402 hasAuthorship W4213022402A5031306593 @default.
• W4213022402 hasAuthorship W4213022402A5036662227 @default.
• W4213022402 hasAuthorship W4213022402A5036761306 @default.
• W4213022402 hasAuthorship W4213022402A5044194506 @default.
• W4213022402 hasAuthorship W4213022402A5052826456 @default.
• W4213022402 hasAuthorship W4213022402A5061753488 @default.
• W4213022402 hasAuthorship W4213022402A5065226003 @default.
• W4213022402 hasAuthorship W4213022402A5067550666 @default.
• W4213022402 hasAuthorship W4213022402A5074582149 @default.
• W4213022402 hasConcept C120665830 @default.
• W4213022402 hasConcept C121332964 @default.
• W4213022402 hasConcept C121608353 @default.
• W4213022402 hasConcept C126322002 @default.
• W4213022402 hasConcept C137403100 @default.
• W4213022402 hasConcept C138816342 @default.
• W4213022402 hasConcept C142724271 @default.
• W4213022402 hasConcept C144024400 @default.
• W4213022402 hasConcept C149923435 @default.
• W4213022402 hasConcept C19165224 @default.
• W4213022402 hasConcept C2250968 @default.
• W4213022402 hasConcept C2780192828 @default.
• W4213022402 hasConcept C2908647359 @default.
• W4213022402 hasConcept C3020641676 @default.
• W4213022402 hasConcept C535046627 @default.
• W4213022402 hasConcept C61511704 @default.
• W4213022402 hasConcept C71924100 @default.
• W4213022402 hasConcept C74909509 @default.
• W4213022402 hasConcept C99454951 @default.
• W4213022402 hasConceptScore W4213022402C120665830 @default.
• W4213022402 hasConceptScore W4213022402C121332964 @default.
• W4213022402 hasConceptScore W4213022402C121608353 @default.
• W4213022402 hasConceptScore W4213022402C126322002 @default.
• W4213022402 hasConceptScore W4213022402C137403100 @default.
• W4213022402 hasConceptScore W4213022402C138816342 @default.
• W4213022402 hasConceptScore W4213022402C142724271 @default.
• W4213022402 hasConceptScore W4213022402C144024400 @default.
• W4213022402 hasConceptScore W4213022402C149923435 @default.
• W4213022402 hasConceptScore W4213022402C19165224 @default.
• W4213022402 hasConceptScore W4213022402C2250968 @default.
• W4213022402 hasConceptScore W4213022402C2780192828 @default.
• W4213022402 hasConceptScore W4213022402C2908647359 @default.
• W4213022402 hasConceptScore W4213022402C3020641676 @default.
• W4213022402 hasConceptScore W4213022402C535046627 @default.
• W4213022402 hasConceptScore W4213022402C61511704 @default.
• W4213022402 hasConceptScore W4213022402C71924100 @default.
• W4213022402 hasConceptScore W4213022402C74909509 @default.
• W4213022402 hasConceptScore W4213022402C99454951 @default.
• W4213022402 hasIssue "6_suppl" @default.
• W4213022402 hasLocation W42130224021 @default.
• W4213022402 hasOpenAccess W4213022402 @default.
• W4213022402 hasPrimaryLocation W42130224021 @default.
• W4213022402 hasRelatedWork W1679275453 @default.
• W4213022402 hasRelatedWork W172283860 @default.
• W4213022402 hasRelatedWork W2016710456 @default.
• W4213022402 hasRelatedWork W2020594847 @default.
• W4213022402 hasRelatedWork W2029279056 @default.
• W4213022402 hasRelatedWork W2112545136 @default.
• W4213022402 hasRelatedWork W2155073391 @default.
• W4213022402 hasRelatedWork W2337979365 @default.
• W4213022402 hasRelatedWork W2366215656 @default.
• W4213022402 hasRelatedWork W3083166703 @default.
• W4213022402 hasVolume "40" @default.
• W4213022402 isParatext "false" @default.
• W4213022402 isRetracted "false" @default.
• W4213022402 workType "article" @default.